Thymosins: chemistry and biological properties in health and disease

Bibliography

• GOLDSTEIN AL, GUHA A, HOWE ML,WHITE A: Ontogenesis of cell-mediated immunity in murine thymocytes and spleen cells and its acceleration by thymosin, a thymic hormone. bninunol. (1971) 106:773–780.
   Google Scholar
• HOROWITZ S, BORCHERDING W, MOORTHY AV et al: Induction of suppressor T cells in systemic lupus erythematosus by thymosin and cultured thymic epithelium. Science (1977) 197(4307):999–1001.
   PubMed Web of Science ®Google Scholar
• MALINDA KM, GOLDSTEIN AL, KLEINMAN HK: Thymosin 134 stimulates directional migration of human umbilical vein endothelial cells. FASEB .1. (1997) 11:474–481.
   PubMed Web of Science ®Google Scholar
• MALINDA KM, SIDHU GS, BANAUDHA KK et al.: Thymosin stimulates endothelial cell migration, angiogenesis, and wound healing. IminunoL (1998) 160:1001–1006.
   PubMed Web of Science ®Google Scholar
• SANDERS MC, GOLDSTEIN AL, WANG YL: Thymosin 134 (Fx peptide) is a potent regulator of actin polymerization in living cells. Proc. NatL Acad. Sci. USA (1992) 89:4678–4682.
   PubMed Web of Science ®Google Scholar
• SOSNE G, SZLITER EA, BARRETT R, KERNACKI KA, KLEINMAN H, HAZLETT LD: Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury. Exp. Eye Res. (2002) 74:293–299.
   PubMed Web of Science ®Google Scholar
• SOSNE G, HAFEEY S, GREENBERY H, KURPAKUS-WHEATE M: Thymosin 134 promotes human conjunctival epithelial cell migration. Curl-. Eye Res. (2003) 24:268–273.
   Web of Science ®Google Scholar
• HIROKAWA K, MCCLURE JE, GOLDSTEIN AL: Age-related changes in localization of thymosin in the human thymus. Thymus (1982) 4:19–29.
   PubMedGoogle Scholar
• DALAKAS MC, ENGEL WK, MCCLURE JE, GOLDSTEIN AL: Thymosin al in myasthenia gravis. N Engl. .1. Med. (1980) 302:1092–1093.
   PubMed Web of Science ®Google Scholar
• ASANUMA Y, GOLDSTEIN AL, WHITE A: Reduction in the incidence of wasting disease in neonatally thymectomized CBA/W mice by the injection of thymosin. Endocrinology (1970) 86:600–610.
   PubMed Web of Science ®Google Scholar
• WARA DW, GOLDSTEIN AL, DOYLE N, AMMANN AJ: Thymosin activity in patients with cellular immunodeficiency. N Engl. Med (1975) 292:70–74.
   PubMed Web of Science ®Google Scholar
• WHITE A, GOLDSTEIN AL: Is the thymus an endocrine gland? Old problem, new data. Perspect. Biol. Med. (1968) 11:475–489.
   PubMed Web of Science ®Google Scholar
• MILLER JF: AP Immunology function of the thymus. Lancet (1961) 2:748–751.
   PubMed Web of Science ®Google Scholar
• GOOD RA, DALMASSO AP, MARTINEZ C, ARCHER OK, PIERCE JC, PAPERMASTER BW: The role of the thymus in development of immunologic capacity in rabbits and mice. .1. Exp. Med. (1962) 116:773.
   PubMed Web of Science ®Google Scholar
• BEARD J: The true function of the thymus. Lancet (1899):144–148.
   Google Scholar
• PAPPENHEIMER AM. The effects of early extirpation of the thymus in albino rats. .1. Exp. Med. (1914) 19:319–327.
   PubMedGoogle Scholar
• KLEIN JJ, GOLDSTEIN AL, WHITE A: Enhancement of in vivo incorporation of labeled precursors into DNA and total protein of mouse lymph nodes after administration of thymic extracts. Proc. Natl. Acad. Sci. USA (1965) 53:812–817.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN AL, SLATER FD, WHITE A: Preparation, assay and partial purification of a thymic lymphocytopoietic factor (thymosin). Proc. Natl. Acad. Sci. USA (1966) 56:1010–1017.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN AL, LOW TLK, THURMAN GB et aL: Current status of thymosin and other hormones of the thymus gland. Recent Frog. Horin. Res. (1981) 37:369–415.
   PubMedGoogle Scholar
• GOLDSTEIN AL, HALL NRS: The endocrine thymus. In: Principles and Practice of Endocrinology and Metabolism. Lippincott Williams & Wilkins: A Wolters Kluwer Company, Philadelphia, PA, USA (2001):1748–1754.
   Google Scholar
• HOOPER JA, MCDANIEL MC, THURMAN GB, COHEN GH, SCHULOF RS, GOLDSTEIN AL: The purification and properties of bovine thymosin. Ann. NY Acad. Sci. (1975) 249:125–144.
   PubMed Web of Science ®Google Scholar
• Investigational New Drug (IND) Application #10,758 issued by the US Food and Drug Administration FDA in March, 1974 to Allan L Goldstein at the University of Texas Medical Branch in Galveston, Texas.
   Google Scholar
• GOLDSTEIN AL: Thymosin al: current status of human trials and potential applications in clinical therapy. In: Thymic Peptides in Preclinical and Clinical Medicine. Maurer HR, Goldstein AL, Hager ED (Eds), W. Zuckschwerdt Verlag, Munich (1997):131–153.
   Google Scholar
• LLOYD MJ, CLEARY PA, PALASZYNSKI SR et al.: A randomized trial to evaluate the immunorestorative properties of synthetic thymosin al in patients with lung cancer. J. Biol. Response Modif (1985) 4:147–158.
   PubMedGoogle Scholar
• MUTCHNICK MG, APPLEMAN HD, CHUNG HT et al.: Thymosin treatment of chronic hepatitis B: a placebo controlled trial. Hepatology (1991) 14:409.
   PubMed Web of Science ®Google Scholar
• SHERMAN KE, SJOGREN M, CREAGER RL et al.: Combination therapy with thymosin and interferon for the treatment of chronic hepatitis C infection: a randomized, placebo-controlled double-blind trial. Hepatology (1998) 27:1128–1135.
   PubMed Web of Science ®Google Scholar
• MCCONNELL L, GRAVENSTEIN S, ROECKER E et al.: Augmentation of influenza antibody levels and reduction in attack rates in elderly subjects by thymosin al. Gerontologist (1989) 29:188A.
   Google Scholar
• PANNEERSELVAM C, WELLNER D, HORECKER BL: The amino acid sequence of bovine thymus prothymosin alpha. Arch. Biochem. Biophys. (1988) 265:454–457.
   PubMed Web of Science ®Google Scholar
• LOW TLK, THURMAN GB, MCADOO M et al.: The chemistry and biology of thymosin. I. Isolation, characterization and biological activities of thymosin al and polypeptide 131 from calf thymus.j Biol. Chem. (1979) 254:981–986.
   Google Scholar
• GARACI E: Combination treatment with zidovudine, thymosin al, and interferon a in human immunodeficiency virus infection. Int. J. Clin. Res. (1994) 24:23–28.
   PubMedGoogle Scholar
• CHADWICK D, PIDO-LOPEZ J, PIRES A et al: A pilot study of the safety and efficacy of thymosin alpha 1 in augmenting immune reconstitution in HIV-infected patients with low CD4 counts taking highly active antiretroviral therapy. Clin. Exp. Immunol (2003) 134:477–81.
   PubMed Web of Science ®Google Scholar
• SZTEIN MB, SERRATE SA, GOLDSTEIN AL: Modulation of interleukin-2 receptor expression on normal human lymphocytes by thymic hormones. Proc. Natl. Acad. Sci. USA (1986) 83:6107–6111.
   PubMed Web of Science ®Google Scholar
• GIULIANI C, NAPOLITANO G, MASTINO A et al.: Thymosin-alphal regulates MHC class 1 expression in FRTL-5 cells at transcriptional level. Eur. I Immunol (2000) 30:778–786.
   PubMed Web of Science ®Google Scholar
• LOW TLK, GOLDSTEIN AL: Chemical characterization of thymosin 134. Biol. Chem. (1982) 257:1000–1006.
   Web of Science ®Google Scholar
• HUFF T, CHRISTIAN SG, MULLER AM, OTTO RN, HANNAPPEL E: 13 Thymosins, small acidic peptides with multiple functions. Int. .1. Biochem. Cell Biol. (2001) 33:205–220.
   Google Scholar
• HUFF T, OTTO AM, CHRISTIAN SG, MULLER MM, HANNAPPEL E: Thymosin P4 is released from human blood platelets and attached by Factor XIIIa (transglutaminase) to fibrin and collagen. FASEB J. (2002) 16:691–696.
   PubMed Web of Science ®Google Scholar
• GRANT DS, KINSELLA JL, KIBBEY MC et al.: Matrigel induces thymosin 134 gene in differentiating epithelial cells. J. Cell Sci. (1995) 108:3685–3694.
   PubMed Web of Science ®Google Scholar
• PHILIP D, HUFF T, GHO Y-S, HANNAPPEL E, KLEINMAN HK: The actin binding site on thymosin P4 promotes angiogenesis. FASEB J. (2003) 17:2103–2108.
   PubMedGoogle Scholar
• YOUNG JD, LAWRENCE AJ, MACLEAN AG et al.: Thymosin beta 4 sulfoxide is an anti-inflammatory agent generated by monocytes in the presence of glucocorticoids. Nat. Med. (1999) 5:1424–1427.
   PubMed Web of Science ®Google Scholar
• GOMEZ-MARQUEZ J, DOSIL M, SEGADEO F et al.: Thymosin-beta 4 gene. Preliminary characterization and expression in tissues, thymic cells and lymphocytes. Immunology (1989) 143:2740–2744.
   Google Scholar
• RUDIN CM, ENGLER P, STORB U: Differential splicing of thymosin beta 4 mRNA. I Immunol (1990) 144:4857–4862.
   PubMed Web of Science ®Google Scholar
• GIRARDI M, SHERLING MA, FILLER RB et al.: Anti-inflammatory effects in the skin of thymosin-beta 4. Immunology (2003) 109:1–7.
   PubMed Web of Science ®Google Scholar
• BADAMCHIAN M, FAGARASAN M, DANNER RL, SUFFREDINI AF, DAMAVANDY H, GOLDSTEIN AL: Thymosin P4reduces lethality and down-regulates inflammatory mediators in endotcodn-induced septic shock. Int. Immunopharmacol (2003) 3:1225–1233.
   PubMed Web of Science ®Google Scholar
• MALINDA KM, SIDHU GS, MANI H et al.: Thymosin B4 accelerates wound healing. J. Investig. Dermatol (1999) 113:364–368.
   PubMed Web of Science ®Google Scholar
• PHILIP D, BADAMCHIAN M, SCHEREMETA B, NGUYEN M, GOLDSTEIN AL, KLEINMAN HK: Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. Wound Repair Regen. (2003) 11:19–24.
   PubMed Web of Science ®Google Scholar
• CHA HJ, JEONG MJ, KLEINMAN HK: Role of thymosin beta 4 in tumor metastasis and angiogenesis. Nati Cancer Inst. (2003) 95(22):1674–1680.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN AL: Thymosin 134: a new molecular target for antitumor strategies. J. Nati Cancer Inst. (2003) 95:1646–1647.
   PubMed Web of Science ®Google Scholar
• PAZMINO NH, IHLE JN, GOLDSTEIN AL: Induction in vivo and M vitro of terminal deoxynucleotidyl transferase by thymosin in bone marrow cells from athymic mice. " Exp. Med. (1978) 147:708–718.
   PubMed Web of Science ®Google Scholar
• HU SK, LOW TLK, GOLDSTEIN AL: Modulation of terminal deoxynucleotidyl transferase activity by thymosin. Ma Cell. Biochem. (1981) 41:49–58.
   PubMed Web of Science ®Google Scholar
• THURMAN GB, LOW TLK, ROSSIO JL,GOLDSTEIN AL: Specific and non-specific macrophage migration inhibition. In: Lymphokines and Thymic Hormones: Their Potential M Cancer Therapeutics, Goldstein AL, Chirigos M (Eds), Raven Press, New York, USA (1981):145–157.
   Google Scholar
• REBAR RW, MIYAKE A, LOW TLK, GOLDSTEIN AL: Thymosin stimulates secretion of luteinizing hormone-releasing factor. Science (1981) 214:669–671.
   PubMed Web of Science ®Google Scholar
• HALL NR, GOLDSTEIN AL: Thymosins stimulate the release of pituitary hormones. Clin. Immunol Newsletter (Elsevier) (1986) 7:99–102.
   Google Scholar
• MOSCINSKI LC, NAYLOR PH, OLIVER J, GOLDSTEIN AL: Thymosin 134 synergizes with human granulocyte-macrophage colony-stimulating factor in maintaining bone marrow proliferation. Immunopharmacology (1993) 26:83–92.
   PubMed Web of Science ®Google Scholar
• BAUMANN CA, BADAMCHIAN M, GOLDSTEIN AL: Thymosin alpha], is a time and dose-dependent antagonist of dexamethasone-induced apoptosis of murine thymocytes in vitro. Int. J. Immunopharmacol (2000) 10:1057–1066.
   Web of Science ®Google Scholar
• MCGILLIS JP, HALL NR, GOLDSTEIN AL: Circadian rhythm of thymosin al in normal and thymectomized mice. J. Immunol (1983) 131(1):148–151.
   PubMed Web of Science ®Google Scholar
• HEALY DL, HODGEN GD, SCHULTE HM et al.: The thymus-adrenal connection: thymosin has corticotropin-releasing activity in primates. Science (1983) 222(4630):1353–1355.
   PubMed Web of Science ®Google Scholar
• MILENKOVIC L, MCCANN SM: Effects of thymosin alpha-1 on pituitary hormone release. Neuroendocrinology(1992) 55:14–19.
   PubMed Web of Science ®Google Scholar
• TURRINI P, TIRASSA P, VIGNETI E, ALOE L: A role of the thymus and thymosin-alpha 1 in brain NGF levels and NGF receptor expression. Neuraimmuna (1998) 82:64–72.
   PubMed Web of Science ®Google Scholar
• HALL NR, MCGILLIS JP, SPANGELO BL, GOLDSTEIN AL: Evidence that thymosins and other biological response modifiers can function as neuroactive immunotransmitters. Innnunol. (1985) 135(2 Suppl.):806s–811s.
   Google Scholar